tiprankstipranks
Trending News
More News >
Elixinol Wellness Ltd (AU:EXL)
:EXL
Advertisement

Elixinol Wellness (EXL) AI Stock Analysis

Compare
8 Followers

Top Page

AU

Elixinol Wellness

(OTC:EXL)

Rating:53Neutral
Price Target:
AU$0.00
▼(-100.00%Downside)
Elixinol Wellness has potential with robust revenue growth but faces significant challenges with profitability and cash flow. The technical analysis provides mixed signals, and the valuation indicates potential overvaluation. Focus on improving profitability and cash flow could enhance the stock's prospects.

Elixinol Wellness (EXL) vs. iShares MSCI Australia ETF (EWA)

Elixinol Wellness Business Overview & Revenue Model

Company DescriptionElixinol Wellness Limited, through its subsidiaries, manufactures and distributes hemp derived nutraceuticals, cosmetics, and food products under the Elixinol and Hemp Foods Australia brands in the Americas, Europe, and Australia. It offers hemp derived cannabidiol and food products, dietary supplements, topicals, and skincare products. The company was formerly known as Elixinol Global Limited and changed its name to Elixinol Wellness Limited in May 2021. The company was incorporated in 2017 and is headquartered in Sydney, Australia.
How the Company Makes MoneyElixinol Wellness makes money primarily through the sale of its hemp-derived products, which include dietary supplements and skincare items. The company's revenue model is centered around direct-to-consumer sales via online platforms, as well as through retail and wholesale distribution channels. Key revenue streams include its branded product lines that cater to different aspects of health and wellness. Additionally, strategic partnerships with retailers and distributors help expand its market presence and drive sales. Significant factors contributing to its earnings include the increasing consumer awareness and demand for natural and plant-based health products, as well as ongoing research and development efforts that lead to innovative product offerings.

Elixinol Wellness Financial Statement Overview

Summary
Elixinol Wellness shows strong revenue growth but remains unprofitable with negative EBIT and net income margins. The balance sheet is stable with low debt levels, but there's a decrease in equity. Cash flow remains negative, indicating a need for improved management.
Income Statement
45
Neutral
Elixinol Wellness shows a significant improvement in revenue, with a growth rate of 80.88% from 2023 to 2024. However, the company remains unprofitable, with negative EBIT and net income margins, indicating ongoing operational challenges. Gross profit margin is positive but needs improvement to achieve sustained profitability.
Balance Sheet
60
Neutral
The company's debt-to-equity ratio remains low at 0.19, indicating a conservative capital structure with manageable debt levels. However, the equity ratio has decreased over time, reflecting a reduction in total assets and equity. Overall, the balance sheet shows stability but requires careful management to improve equity levels.
Cash Flow
50
Neutral
The operating cash flow remains negative, indicating the company is not yet generating cash from its operations. Free cash flow is also negative, although there is a slight improvement in free cash flow growth. The company relies on financing to support its cash needs, suggesting a need for improved cash management.
BreakdownDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue14.96M8.27M7.05M9.34M15.01M
Gross Profit5.36M3.27M-3.27M-6.25M-9.58M
EBITDA-4.06M-6.81M-9.28M-15.51M-23.36M
Net Income-1.72M-7.51M-10.57M-17.02M-104.51M
Balance Sheet
Total Assets18.45M11.71M13.48M25.33M42.47M
Cash, Cash Equivalents and Short-Term Investments1.08M708.00K2.86M12.65M27.74M
Total Debt1.94M1.26M1.83M2.65M2.65M
Total Liabilities8.42M5.25M4.33M6.25M6.82M
Stockholders Equity10.03M6.46M9.16M19.08M35.65M
Cash Flow
Free Cash Flow-3.53M-2.77M-8.16M-14.36M-22.95M
Operating Cash Flow-3.47M-2.76M-8.15M-14.07M-22.62M
Investing Cash Flow-66.00K-1.04M-869.00K172.00K2.55M
Financing Cash Flow3.92M1.61M-757.00K-1.16M27.55M

Elixinol Wellness Peers Comparison

Overall Rating
UnderperformOutperform
Sector (46)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
AUEXL
53
Neutral
AU$3.91M-21.29%80.87%82.44%
46
Neutral
C$197.02M-3.33-23.14%2.65%20.75%-0.36%
$6.77M-164.01%
$4.74M-55.38%
$4.69M
AUAGH
53
Neutral
AU$23.85M-218.38%-14.30%29.69%
AUBOD
39
Underperform
AU$4.26M
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
AU:EXL
Elixinol Wellness
0.02
-0.02
-51.43%
CNGGF
Cann Group
0.03
<0.01
50.00%
EOFBF
Ecofibre
0.01
-0.04
-80.00%
HDRPF
Epsilon Healthcare Limited
AU:BOD
Bod Australia Ltd
0.02
0.00
0.00%
AU:AGH
Althea Group Holdings Ltd.
0.03
<0.01
50.00%

Elixinol Wellness Corporate Events

Elixinol Wellness Addresses Late Lodgement of Appendix 3Y
Jul 16, 2025

Elixinol Wellness Ltd announced a late lodgement of Appendix 3Y due to an administrative oversight related to a change in director’s interest. The company has acknowledged its obligations under ASX Listing Rules and has implemented measures to improve its internal processes to ensure future compliance, reflecting its commitment to transparency and regulatory adherence.

Elixinol Wellness Expands Market Presence with New Securities Quotation
Jun 30, 2025

Elixinol Wellness Limited announced the quotation of 799,855 ordinary fully paid securities on the Australian Securities Exchange (ASX) as of June 27, 2025. This move is part of their strategic financial operations, potentially enhancing their market presence and providing additional liquidity for stakeholders.

Elixinol Wellness Strengthens Leadership with Key Appointments
Jun 19, 2025

Elixinol Wellness Limited has announced significant executive leadership changes, appointing Natalie Butler as the new Chief Executive Officer and Adam Dimitropoulos as the Chief Financial Officer. These appointments are aimed at strengthening the company’s leadership team and positioning it for growth. Natalie Butler, who has been instrumental in leading the company through a complex period, is expected to drive the next phase of the company’s strategic priorities. Adam Dimitropoulos brings extensive financial and operational expertise, which will support Elixinol’s focus on delivering sustained profitability. The company acknowledges the contributions of outgoing CFO Josephine Lorenz and wishes her well in her future endeavors.

Elixinol Wellness Announces Cessation of Securities
Jun 11, 2025

Elixinol Wellness Limited announced the cessation of 16,375,097 securities due to the expiry of options or other convertible securities without exercise or conversion. This development may impact the company’s capital structure and could influence stakeholder perceptions regarding the company’s financial strategies and market positioning.

Elixinol Wellness Announces New Securities Issuance
Jun 4, 2025

Elixinol Wellness Limited has announced a proposed non-pro rata offer of securities, planning to issue up to 100,000 ordinary fully paid shares. This move is part of the company’s strategy to raise capital, potentially impacting its market positioning and providing opportunities for investors to participate in the company’s growth.

Elixinol Wellness Limited Announces New Share Offering
Jun 4, 2025

Elixinol Wellness Limited has announced a prospectus for offering up to 100,000 new shares at an issue price of $0.1 per share, aiming to raise up to $10,000. This move is intended to remove trading restrictions on the sale of shares issued under this offer and prior to the prospectus date. The offer is considered speculative, and potential investors are advised to seek professional advice due to associated risks. The prospectus is not for distribution in the United States and is subject to legal restrictions in other jurisdictions.

Elixinol Wellness Announces Quotation of New Securities on ASX
Jun 4, 2025

Elixinol Wellness Limited announced the quotation of 8,571,429 ordinary fully paid securities on the Australian Securities Exchange (ASX). This move is part of a previously announced transaction, potentially enhancing the company’s market presence and providing additional capital for its operations, which could have positive implications for its stakeholders.

Elixinol Wellness to Resume Trading After Financing Announcement
May 21, 2025

Elixinol Wellness Limited, a company listed on the ASX, has announced that the suspension of its securities trading will be lifted following a new financing and capital arrangement. This development is expected to impact the company’s operations positively by resuming trading, potentially enhancing its market position and providing clarity to stakeholders.

Elixinol Wellness Announces Proposed Securities Issue to Boost Growth
May 21, 2025

Elixinol Wellness Limited has announced a proposed issue of 8,571,429 ordinary fully paid securities, set to be issued on May 28, 2025. This strategic move is aimed at enhancing the company’s financial flexibility and supporting its growth initiatives, potentially strengthening its position in the wellness market.

Elixinol Wellness Secures $1.5M Funding to Boost Automation and Brand Growth
May 21, 2025

Elixinol Wellness Ltd has successfully raised $1.5 million through a combination of debt and equity to enhance its operational capabilities. The funds will be used to build inventory for its brands, automate manufacturing processes, and drive brand growth, positioning the company for improved margins and revenue growth. This strategic move is expected to strengthen Elixinol’s market position and operational efficiency, benefiting stakeholders and aligning with its growth objectives.

Elixinol Wellness Ltd Announces AGM Results with All Resolutions Passed
May 20, 2025

Elixinol Wellness Ltd announced the results of its Annual General Meeting, where all resolutions were carried, including the adoption of the remuneration report, re-election of a director, renewal of the equity plan, and approval of an additional placement capacity. These outcomes reflect shareholder support and may enhance the company’s strategic flexibility and governance structure.

Elixinol Wellness FY24 AGM Highlights Investment Risks and Uncertainties
May 20, 2025

Elixinol Wellness held its FY24 Annual General Meeting, providing general information about the company’s operations and investment risks. The presentation emphasized that it is not an investment recommendation and highlighted the uncertainties associated with forward-looking statements, urging investors to seek independent advice.

Elixinol Wellness Reports Strong Growth and Strategic Expansion Plans for 2025
May 20, 2025

Elixinol Wellness has made significant progress in 2024, achieving an 81% increase in group revenue to $15 million, driven by strategic acquisitions and operational efficiencies. The company plans to continue its growth trajectory in 2025 by focusing on execution, scaling operations, and expanding its product offerings, particularly in the e-commerce and healthy snacking sectors, to enhance profitability and market reach.

Elixinol Wellness Extends Voluntary Suspension for Capital Raising Approval
May 19, 2025

Elixinol Wellness Ltd announced an extension of the voluntary suspension of its securities until May 21, 2025, due to the need for additional time to finalize ASX approval for its capital raising structure. This extension indicates ongoing efforts to secure financial stability and may impact the company’s market operations and stakeholder confidence.

Elixinol Wellness Requests Voluntary Suspension Pending Financing Announcement
May 15, 2025

Elixinol Wellness Limited, a company listed on the Australian Securities Exchange, has requested a voluntary suspension of its securities from trading. This suspension is pending an announcement regarding a potential financing or capital raising arrangement. The company aims to manage its continuous disclosure obligations effectively and expects to make the announcement before the commencement of normal trading on May 19, 2025.

Elixinol Wellness Initiates Trading Halt for Pending Announcement
May 13, 2025

Elixinol Wellness Limited, a company listed on the Australian Securities Exchange, has requested a trading halt on its securities. This pause in trading is due to an impending announcement regarding a potential financing or capital raising arrangement. The halt is expected to last until the company releases its announcement or until normal trading resumes on May 15, 2025. The move indicates a significant corporate development that could impact the company’s financial structure and market position.

Elixinol Wellness Reports Q1 FY25 Revenue Growth Amid Strategic Realignment
Apr 30, 2025

Elixinol Wellness reported a 13.7% increase in revenue year-on-year for Q1 FY25, despite a decrease from the previous quarter due to timing delays and retail range rationalization. The company is undergoing structural realignment and cost-saving initiatives to strengthen its financial position, with new product launches and market expansions expected to drive growth in the latter half of 2025.

Elixinol Wellness Addresses ASX Price Query Amid Trading Fluctuations
Apr 30, 2025

Elixinol Wellness Limited, a company listed on the ASX, has responded to a price query from the ASX regarding a recent drop in its securities’ price and a significant increase in trading volume. The company stated that it is not aware of any undisclosed information that could explain the recent trading activity and confirmed its compliance with ASX listing rules.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Jul 11, 2025